One-Shot cell therapy trial aims to reset immune system in devastating nerve diseases
NCT ID NCT07337785
Summary
This early-stage study is testing a new, 'universal' CAR-T cell therapy in adults with severe, hard-to-treat neurological autoimmune diseases like multiple sclerosis and myasthenia gravis. The goal is to see if a single infusion of these engineered immune cells is safe and can reduce disease activity by targeting and removing harmful B cells. Researchers will enroll up to 36 participants to monitor for side effects and early signs that the treatment might help control these chronic conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING OR REFRACTORY MULTIPLE SCLEROSIS (MS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.